Evidence map›Paper›PMID 41583531›Full record

ArticleInternational journal of medical sciences2026

Transcriptomic Profiling Reveals Divergent Immune Responses to AAV1 and AAV-ie in Mice Inner Ear.

Dazhi Shi, Lei Han, Can Li, Guannan Geng, Luoying Jiang, Xiaoyun Chen, Fengzhao Yang, Yong Feng, Junli Luo, Yilai Shu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Recent Progress in Mechanism-Based Therapies forInternational journal of molecular sciences · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Dazhi ShiDepartment of Otorhinolaryngology, The Second Affiliated Hospital, Hengyang Medical School, University of South China; Hengyang, 421001 China.
Lei HanENT Institute and Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan University, Shanghai 200031, China.
Can LiDepartment of Otorhinolaryngology, The Second Affiliated Hospital, Hengyang Medical School, University of South China; Hengyang, 421001 China.
Guannan GengENT Institute and Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan University, Shanghai 200031, China.
Luoying JiangENT Institute and Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan University, Shanghai 200031, China.
Xiaoyun ChenENT Institute and Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan University, Shanghai 200031, China.
Fengzhao YangDepartment of Otolaryngology, The First Affiliated Hospital of Nanchang University; Nanchang, 330006, China.
Yong FengDepartment of Otorhinolaryngology, The Affiliated Changsha Central Hospital, Hengyang Medical School, MOE Key Lab of Rare Pediatric Diseases & Institute for Future Sciences, University of South China; Changsha, 410028, China.
Junli LuoDepartment of Otorhinolaryngology, The Second Affiliated Hospital, Hengyang Medical School, University of South China; Hengyang, 421001 China.
Yilai ShuDepartment of Otorhinolaryngology, The Second Affiliated Hospital, Hengyang Medical School, University of South China; Hengyang, 421001 China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Adeno-associated virus (AAV) unequivocally emerges as one of the most powerful and promising delivery vectors for gene therapy targeting hereditary hearing loss. Following AAV transduction in the inner ear, varying degrees of natural immune responses are triggered, primarily characterized by macrophage activation and the secretion of pro-inflammatory factors. Additionally, the production of neutralizing antibodies may affect the efficacy of gene therapy. To evaluate immune dynamics, we injected AAV1 and AAV-ie (capsids with distinct transfection efficiencies) into murine cochleae and analyzed temporal transcriptomic profiles. Our results demonstrate that both capsids induce immune activity but with critical temporal and intensity differences that AAV1 elicits significantly later and milder immune reactions compared to AAV-ie. These findings establish that dynamic cochlear gene expression profiles directly inform the selection of immunologically optimized AAV vectors to minimize adverse responses in future hereditary hearing loss gene therapies.

Indexed as

DependovirusEar, InnerHearing LossAnimalsCochleaGene Expression ProfilingGene Therapy AgentsGenetic TherapyGenetic VectorsHumansMiceTranscriptomeTransduction, Genetic

Identifiers

PMID41583531
PMCPMC12825142

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.